Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Categories: @vaccine-makers   

Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Website: jnj.com


  • Good financial results growth rate 42.8% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (16.4%)
  • Dividend yield for the last twelve months 2.5%
  • Free cash flow yield -1.8% (LTM)
  • Share price is 46.3% higher than minimum and 1.8% lower than maximum for the last 3 years
  • The company is undervalued by EV / LTM EBITDA multiple compared to target level (14.8x vs
    )
  • Fundamental value created in LTM (estimate)

Key Financials (Download financials)

Ticker: JNJ
Share price, USD:  (-1.0%)207.78
year average price 168.90  


year start price 145.05 2024-12-27

min close price 142.06 2025-01-10

max close price 211.58 2025-12-13

current price 207.78 2025-12-26
Common stocks: 2 631 399 832

Dividend Yield:  2.5%
FCF Yield LTM: -1.8%
EV / LTM EBITDA: 14.8x
EV / EBITDA annualized: 15.5x
Last revenue growth (y/y):  +6.8%
Last growth of EBITDA (y/y):  +78.8%
Historical revenue growth:  +2.3%
Historical growth of EBITDA:  +30.5%
Target EV / EBITDA (hist percentile):
Express share price potential:
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 546 752
Net Debt ($m): 27 233
EV (Enterprise Value): 573 985
EBITDA LTM ($m): 38 890
EV / LTM EBITDA: 14.8x
Price to Book: 6.9x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-12-23nypost.com

J&J ordered to pay record $1.5B in talc cancer lawsuit — while vowing to appeal ‘unconstitutional' ruling

2025-12-23zacks.com

JNJ's Tremfya Gets EU Approval for Pediatric Plaque Psoriasis

2025-12-23zacks.com

Stormy 2026? 3 Defensive Stocks to Weather a Recession

2025-12-23zacks.com

J&J Wins FDA Nod for Subcutaneous Version of NSCLC Drug Rybrevant (Revised)

2025-12-23reuters.com

J&J vows appeal after US jury hits it with record $1.5 billion talc cancer award

2025-12-22businesswire.com

Over $1.5 Billion Baltimore Verdict Holds Johnson & Johnson Liable Over Iconic Baby Powder

2025-12-22zacks.com

J&J Stock Trading Above 50- & 200-Day SMA for 6 Months: How to Play

2025-12-20nypost.com

Minnesota jury says Johnson & Johnson owes $65.5 million to woman with cancer who used talcum powder

2025-12-19businesswire.com

Minnesota Jury Delivers $65.5 Million History-Making Verdict Against Johnson & Johnson

2025-12-18zacks.com

J&J Wins FDA Nod for Subcutaneous Version of NSCLC Drug Rybrevant
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data